KLAC — KLA Corporation

As of 2026-08-27, the tape is cautious: the stock sits below its 20- and 50-day moving averages and RSI is 40.4. That said, the Q4 FY26 beat, Q1 FY27 revenue guide of ~$4.0B, and a 28-buy/14-hold/2-sell analyst breakdown keep the fundamental backdrop positive. The Street's average target of roughly $225-242 implies meaningful upside, but near-term sentiment is capped by export-control headlines.

Revenue has inflected upward after a mid-cycle pause: YoY growth went from roughly 24-30% during FY25 down to a 7.2% low in Q2 FY26, then reaccelerated to 11.5% in Q3 FY26 and 15.2% in Q4 FY26. Q4 FY26 revenue of $3.66B and GAAP EPS of $1.04 were record prints, and operating margin held near 42%. The one blemish is quarterly OCF, which dipped to $906M in Q4 FY26 from $1.16B a year earlier—likely working-capital timing, since FY26 free cash flow still came in at $3.77B. The trajectory looks like a cyclical upturn, not a structural deceleration.

Expensive on trailing metrics but less so on forward numbers. As of 2026-08-27, KLAC trades at 49.9x TTM EPS and 17.7x TTM sales, well above its 5-year averages of 37.3x earnings and 12.4x sales. On FY27 consensus EPS of $5.48, the forward P/E drops to about 33.5x, slightly below that 5-year average—so the market is paying for a growth recovery but not pricing in an obvious bubble.

At $183.77, the market is effectively pricing ~$5.48 of FY27 EPS at 33.5x. That embeds a strong recovery—Q1 FY27 guidance of $4.0B revenue is roughly 25% above the prior-year quarter. If the AI/advanced-packaging cycle exceeds estimates, the multiple has room to re-rate toward the 37x historical norm; if China export controls tighten or the capex cycle slows, the stock is vulnerable because the TTM multiple offers no cheapness cushion.

As of 2026-08-27, RSI is 40.4—weak but not oversold. Price sits 4.5% below the 20-day SMA, 14.5% below the 50-day SMA, yet 8.3% above the 200-day SMA. That is a corrective pullback inside a longer-term uptrend. For an entry, waiting for either a 200-day retest or a confirmed RSI reclaim above 50 would offer a better risk/reward than chasing here.

• Potential tightening of U.S. export controls on China—a key source of WFE demand—remains the largest macro overhang.
• AI infrastructure, advanced packaging, and HBM buildouts are driving content growth for process control and inspection.
• Semiconductor capital spending is cyclical; memory/foundry capex swings can swing KLA's revenue double-digits.
• Higher-for-longer interest rates pressure high-multiple technology valuations, making KLA's 33.5x forward multiple sensitive to rate moves.
• Government subsidies and fab localization (CHIPS-type programs) are adding wafer capacity and inspection demand.

• Q1 FY27 earnings (late October 2026) will be the first test of the $4.0B revenue/$1.16 EPS guidance.
• September 2026 investor conferences (Citi TMT on 9/9, Goldman Communacopia on 9/11) could provide more granular advanced-packaging commentary.
• Clarity or relief on China export-control policy could remove the overhang and trigger a re-rating.
• Continued HBM/advanced-packaging capacity announcements from memory/logic leaders.

• Escalating U.S.-China export controls could restrict sales to a major region and hit both revenue and backlog.
• Semiconductor capex is cyclical; an AI capex digestion period would compress orders and margins.
• Valuation risk: 17.7x TTM sales and a 49.9x TTM P/E leave little room for a growth miss.
• Customer concentration in a handful of leading-edge logic/memory makers means order timing can be lumpy.
• Positive accrual ratio suggests reported earnings are running ahead of cash generation, a minor earnings-quality flag.

KLA is the dominant process-control franchise in an AI-led upcycle; the Q4 beat and Q1 guide suggest the growth engine is reaccelerating. At $183.77 the stock is fairly valued on forward earnings but rich on trailing sales, with China export controls as the swing factor. It's a quality compounder to own on pullbacks, but not a clear bargain at this exact price.

Applied a 35x forward P/E to FY27 consensus EPS of $5.48—a discount to KLAC's 5-year average P/E of 37.3x to reflect China export-control and cyclical risk. That yields $191.9, close to the current price and below the Street's ~$225 consensus, consistent with 'fairly valued with real upside if the cycle delivers.'